ElevateBio

ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines.

[ElevateBio @elevatebio]

Check out our latest piece in @GENbio, exploring how ElevateBio is using generative AI to overcome the limitations of naturally occurring proteins in gene editing. Read more: https://t.co/5I1HgHPYg3

[ElevateBio @elevatebio]

Yogesh Waghmare will present at CGT Talk 2026 to discuss how ElevateBio is using AI to make better use of manufacturing information captured across documents and help subject matter experts work more efficiently.

[ElevateBio @elevatebio]

No one wants a complete response letter (CRL) setback. 4 ways to ensure your CDMO is ready.

Read more: https://t.co/qKAvnMVdfB

[ElevateBio @elevatebio]

From early discovery & process development through commercial cGMP manufacturing, we've built an end-to-end ecosystem that keeps programs moving forward – so partners never have to start over with a new provider.

Learn more: https://t.co/d1zI6Mi8Od

[ElevateBio @elevatebio]

From demonstrating initial feasibility to engineering clinical candidates and building entire therapeutic pipelines, ElevateBio provides gene editing services to maximize the clinical success of therapeutic programs.

Discover more: https://t.co/HcGuz0dHc9

[ElevateBio @elevatebio]

ElevateBio presented new data at @ASGCTherapy 2026 across 8 posters & 2 oral presentations. The data showcased our targeted gene insertion platform, our new epigenetic editing platform, & continued advances in AI-powered discovery.

Press release: https://t.co/EblcXkRh2Z

[ElevateBio @elevatebio]

The difference speaks for itself. From precise gene-editing tools to AI-driven design, ElevateBio’s robust capabilities support partners’ advanced therapies across the full product lifecycle.

Explore what sets us apart: https://t.co/9EQ9jXOdbf

[ElevateBio @elevatebio]

We're presenting at the International Society for Cell & Gene Therapy held from May 6-9. Chesney Michels will discuss "A Novel Non-Viral Platform Combining a LEG Nuclease and mbDNA™ for High-Efficiency T-Cell Engineering."

Learn more about ISCT: https://t.co/bzxLfK9UQb

[ElevateBio @elevatebio]

We’re sharing new gene editing capabilities at @ASGCTherapy.

ElevateBio will deliver 9 presentations demonstrating the breadth of our genetic medicine platform.

Learn more: https://t.co/xmhlmzFq5E

[ElevateBio @elevatebio]

We offer three structured partnership models that reflect how R&D teams move programs forward. Each path addresses a distinct stage of decision-making. Learn more about the three paths to therapeutic progress: https://t.co/EB0X82fZFS

[ElevateBio @elevatebio]

Through AI, we’re accelerating the development of potentially curative treatments across a broad range of therapeutic areas, drastically cutting timelines on the path towards the clinic. Learn more: https://t.co/zhxc3BsTjF

[ElevateBio @elevatebio]

At @ASGCTherapy, we're highlighting our genetic medicine platform: AI-powered discovery, data from emerging editing modalities, protein engineering expertise, off-target assessment strategies, & our non-viral delivery platform.

Read the press release: https://t.co/Dvig2wjkO8

[ElevateBio @elevatebio]

Ron Chong & Sarah Compton will lead Engineering Precision in Genetic Medicines, a webinar hosted by @OutsourcedPharm to explore how engineering assays, generative AI, & directed evolution can expand the range of addressable diseases. Register: https://t.co/xDTfmtrjVc

[ElevateBio @elevatebio]

Cell therapy manufacturing is complex. Learn the 10 questions to ask when choosing a cell therapy CDMO.

Read more: https://t.co/5x39MdaJ0d

[ElevateBio @elevatebio]

ElevateBio partners with innovators to identify drug targets & manufacture clinical & commercial products to address unmet medical needs. Our capabilities span the full development journey, so your program never has to restart with someone new. Learn more: https://t.co/w2sqXvZ5LQ

[ElevateBio @elevatebio]

Our team is headed to the 2026 Cell & Gene Meeting on the Med. Chief Scientific Officer, Amy Pooler, Ph.D., will present on how ElevateBio supports partners in designing, developing, & manufacturing therapies from early discovery through commercialization. https://t.co/37tSBkEYiu

[ElevateBio @elevatebio]

Our Proof-of-Concept partnership model is designed to answer a foundational development question: can the right gene edit be made for this target? Learn more about our flexible partnership models at https://t.co/JR9txw4wLZ

[ElevateBio @elevatebio]

We're headed to Copenhagen for #CRISPRMED26. Adrian Oliver, Associate Director, Translational Biology, will discuss how ElevateBio has identified editing systems that demonstrated near complete knockdown of the target gene 𝘪𝘯 𝘷𝘪𝘷𝘰.

Register here: https://t.co/BwluJLRkz4

[ElevateBio @elevatebio]

Step inside our manufacturing facility designed to take your therapies from discovery to commercialization. By housing all capabilities under one roof, we streamline the manufacturing process across the entire product lifecycle. Explore more: https://t.co/lHz4PSGHAu

[ElevateBio @elevatebio]

ElevateBio partners get a close-up look at our BaseCamp® facilities, from laboratories to manufacturing suites. Being present in the space alongside our own team builds trust and strengthens collaboration at every stage.

Explore BaseCamp®: https://t.co/WzCkIbYSdl